BioSpace News Archive

Opsens Inc. will host an investor webinar and live Q&A session

The inaugural Women Pharmacist Day will be commemorated on Oct. 12, 2018, in conjunction with National Pharmacist Month, to recognize the important contributions women pharmacists make, every day, to delivering quality care to patients.

In a matter of weeks, recreational cannabis will be legal in Canada, and pot stocks are on a rampage that’s won over even the grizzliest of bears and the most skeptical short-sellers.

CROP Infrastructure Corp., announces that further to its LOI with Naturally Splendid Enterprises (TSX-V: NSP)(OTCQB: NSPDF) (previously announced on August 14th 2018) CROP will utilize NSP’s proprietary HempOmega™ powder created from microencapsulated hemp seed oil in its ‘CannaDrink’ functional beverage line currently being developed.

Evofem Biosciences, Inc. will present an update on the methodology and status of two ongoing late stage clinical trials of its lead product candidate, Amphora®.

Be The Match BioTherapies and Cryoport, Inc. today announced a strategic partnership.

Conagen, an innovative biotechnology company announced today that it had a major breakthrough in developing next-generation natural preservatives through patent-pending technology. This ready-to-go technology will help potential partners with successful commercialization in 2019.

ORHub, Inc. (OTCQB: ORHB) (the “Company” or “ORHub”), a HIPAA compliant, physician-driven digital software company focused on improving profitability and the cost effectiveness of hospitals through real-time smart data and analytics, today announces that ORHub has confirmed an agreement with Baptist Health of Jacksonville, Florida.

ARIKAYCE is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options

Presentation by Dr. Michio Hirano on Mitochondrial DNA Depletion Disorders will Highlight Clinical Data on Treatment of Thymidine Kinase 2 Deficiency with Deoxynucleoside Therapy.